戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 er than the conventional dose used without a hematopoietic growth factor.
2  and IL-3, which is a novel property of this hematopoietic growth factor.
3 oteins is involved in signal transduction of hematopoietic growth factors.
4 ss regulated by a family of lineage specific hematopoietic growth factors.
5 pears to be under the control of an array of hematopoietic growth factors.
6  to expand in liquid cultures in response to hematopoietic growth factors.
7 n analyzed for 41 cytokines, chemokines, and hematopoietic growth factors.
8 o result from the blockade of JAK2-dependent hematopoietic growth factors.
9 s myelotoxicity is prevented with the use of hematopoietic growth factors.
10 ere cultured 4 days in serum-free media with hematopoietic growth factors.
11 e, with no patient requiring transfusions or hematopoietic growth factors.
12 kinase, which is activated in blood cells by hematopoietic growth factors.
13 cells (HSC) can be significantly expanded by hematopoietic growth factors.
14  in methylcellulose medium supplemented with hematopoietic growth factors.
15 ns only), mycophenolate mofetil, and porcine hematopoietic growth factors.
16 esis was not due to redundancy between these hematopoietic growth factors.
17  current evidence on the role of recombinant hematopoietic growth factors.
18 whether survivin expression was regulated by hematopoietic growth factors.
19 kinase is stimulated by various stresses and hematopoietic growth factors.
20 human bone marrow cells to exogenously added hematopoietic growth factors.
21 ), the growth of Mo7e cells was dependent on hematopoietic growth factors.
22 gnal transduction events elicited by several hematopoietic growth factors.
23 es, in the presence of suitable cocktails of hematopoietic growth factors.
24  blood stem cells through synergy with other hematopoietic growth factors, 5) expanding progenitor ce
25                                      It is a hematopoietic growth factor, a cytokine involved in infl
26 HIP(-/-) mice are hyperresponsive to certain hematopoietic growth factors, a phenotype very similar t
27                                         Most hematopoietic growth factors act selectively as survival
28                                              Hematopoietic growth factors allow dose escalation of ch
29 ll factor (SCF), a potent comitogen for many hematopoietic growth factors, also synergized with GM-CS
30                                   The use of hematopoietic growth factors, although well established
31 oral and geographic variations in the use of hematopoietic growth factors among patients receiving ch
32  The contribution of interleukin-3 (IL-3), a hematopoietic growth factor and immunoregulatory cytokin
33 nt of apheresis technology, the discovery of hematopoietic growth factors and small molecule CXCR4 an
34 the molecular cloning and expression of many hematopoietic growth factors and their receptors, as wel
35 ylcellulose cultures in the absence of added hematopoietic growth factors and, at higher frequency, i
36 cyclosporine, mycophenolate mofetil, porcine hematopoietic growth factors, and anti-alphaGal antibody
37 luding: intravenous immunoglobulins, myeloid hematopoietic growth factors, and granulocyte transfusio
38 , pharmacological immunosuppression, porcine hematopoietic growth factors, and immunoadsorption of an
39  gene products of the Wnt family function as hematopoietic growth factors, and that they may exhibit
40                                              Hematopoietic growth factors are being administered to p
41 s) mobilized with high-dose chemotherapy and hematopoietic growth factors are now widely used to supp
42                                              Hematopoietic growth factors are used to reverse chemoth
43 er of the tyrosine kinase receptor family of hematopoietic growth factors, are discussed.
44                                   The use of hematopoietic growth factors as primary prophylaxis may
45 t attempts to ex vivo expand HSPCs have used hematopoietic growth factors but have not achieved clini
46  and differentiation in the absence of added hematopoietic growth factors but that stimulation with c
47         The large majority were dependent on hematopoietic growth factors, but a low frequency of aut
48 lood by a wide variety of stimuli, including hematopoietic growth factors, chemotherapy, and chemokin
49 otics, prokinetics, bile acids, statins, and hematopoietic growth factors could also contribute to am
50  It was also demonstrated that these various hematopoietic growth factors, cytokines, and chemokines
51 in response to a number of stimuli including hematopoietic growth factors, cytotoxic agents, and cert
52 403) into normal mouse bone marrow generates hematopoietic growth factor-dependent cell lines frozen
53 retinoic acid receptor was used to establish hematopoietic growth factor-dependent, lympho-myeloid pr
54                                          The hematopoietic growth factor erythropoietin (Epo) initiat
55                                          The hematopoietic growth factor erythropoietin (Epo) trigger
56 em increasingly treated with the recombinant hematopoietic growth factor erythropoietin.
57 em increasingly treated with the recombinant hematopoietic growth factor erythropoietin.
58 advanced cancer patients with Flt3 ligand, a hematopoietic growth factor, expanded DCs 20-fold in viv
59 O) is a recently characterized member of the hematopoietic growth factor family that serves as the pr
60 matopoietic progenitors, serum levels of the hematopoietic growth factor Flt3 ligand were dramaticall
61                                          The hematopoietic growth factor Flt3L drives the expansion o
62 ents that might influence infection outcome (hematopoietic growth factors, fluconazole, graft-versus-
63 atic allografts from donors treated with the hematopoietic growth factor fms-like tyrosine kinase 3 l
64 row cells expressing p230 required exogenous hematopoietic growth factors for optimal growth, whereas
65 nonanemic low/intermediate-1 IPSS (n = 123), hematopoietic growth factors for patients with anemic lo
66 paB, which results in increased secretion of hematopoietic growth factor G-CSF.
67 gy, cell surface phenotype, or expression of hematopoietic growth factor genes.
68                                          The hematopoietic growth factors granulocyte colony-stimulat
69 ntly been completed evaluating the effect of hematopoietic growth factors (granulocyte-macrophage col
70 human myeloid differentiation induced by the hematopoietic growth factor, granulocyte-macrophage colo
71 egulation of this protein in response to the hematopoietic growth factors, granulocyte-macrophage col
72                          The availability of hematopoietic growth factors has also led to more effect
73                          The introduction of hematopoietic growth factors has been a major advancemen
74                                              Hematopoietic growth factors have made it possible to co
75                                              Hematopoietic growth factors have played a major role in
76                                              Hematopoietic growth factors have shown clinical benefit
77                                              Hematopoietic growth factors (HGF) mobilize potential to
78 RA alone or SCF in combination with 15 other hematopoietic growth factors (HGF) tested.
79                                              Hematopoietic growth factors (HGFs) released by the affe
80                                              Hematopoietic growth factors (HGFs) stimulate growth, di
81 (PHSCs) requires ex vivo culture in multiple hematopoietic growth factors (HGFs) to promote cell divi
82 creased self-renewal capacity in response to hematopoietic growth factors (HGFs).
83 ectin domain family member 11A [CLEC11A]), a hematopoietic growth factor important for development of
84 onate, which is regulated by an early acting hematopoietic growth factor important for the growth and
85 icle reviews the clinical use of old and new hematopoietic growth factors in acquired and inherited b
86 on the patterns and correlates of the use of hematopoietic growth factors in community-dwelling elder
87                      The role of long-acting hematopoietic growth factors in facilitating every-2-wee
88 trated by the heightened growth responses to hematopoietic growth factors in hematopoietic cells of m
89                                  The role of hematopoietic growth factors in lineage commitment and d
90 ransgenic mouse despite normal expression of hematopoietic growth factors in the BM.
91 ss, medical costs, and cost effectiveness of hematopoietic growth factors in the community.
92             This article explores the use of hematopoietic growth factors in the older cancer patient
93 ry patterns of proliferation in a mixture of hematopoietic growth factors in the presence of differen
94 cellulose cultures and treated with selected hematopoietic growth factors in the presence or absence
95 actice guidelines, and practice patterns for hematopoietic growth factors in the supportive care of c
96  (P = 0.57); however, more patients received hematopoietic growth factors in the valganciclovir group
97 C do not proliferate in response to multiple hematopoietic growth factors in vitro and do not radiopr
98 ind and directly regulate the bioactivity of hematopoietic growth factors including interleukin-7 (IL
99 here was an increase in the mRNA for several hematopoietic growth factors including macrophage colony
100 ere is now good evidence that treatment with hematopoietic growth factors, including granulocyte colo
101 ling induced by engineered Notch ligands and hematopoietic growth factors influences hematopoietic st
102 rum-free cultures containing fibronectin and hematopoietic growth factors inhibited myeloid different
103                             We show that the hematopoietic growth factor interleukin (IL)3, maintaine
104 ntibody (mAb), cobra venom factor (CVF), pig hematopoietic growth factors (interleukin-3 (pIL3) and s
105 ontaining medium in the presence of multiple hematopoietic growth factors (interleukin-6, stem cell f
106 ion of DNA plasmids encoding cytokine and/or hematopoietic growth factors, interleukin-2 (IL-2), IL-1
107 t production of certain stromal cell-derived hematopoietic growth factors is deficient as a consequen
108                                      IL-9, a hematopoietic growth factor, is considered to be a media
109 rt by the production of stromal cell-derived hematopoietic growth factors, is impaired.
110                                              Hematopoietic growth factors mediate the survival and pr
111                                              Hematopoietic growth factors mediate their effects on st
112 ting a potential non-hematopoietic effect of hematopoietic growth factors on iron absorption by the g
113 h high-risk aggressive lymphoma by utilizing hematopoietic growth factors or autologous peripheral bl
114 her platelet counts suggest viral effects on hematopoietic growth factors or cytokines.
115 nditions and multipotent cells, mobilized by hematopoietic growth factors or emerging during parasiti
116 hile hepatoblasts were the primary source of hematopoietic growth factors, other stromal cells-includ
117 ormed cells exhibited complete dependency on hematopoietic growth factors, particularly GM-CSF and IL
118 bstantial geographic variation in the use of hematopoietic growth factors, ranging from 10.6% in Seat
119 in 1 transgene by expressing the nonlymphoid hematopoietic growth factor receptor c-MPL (myeloprolife
120                     Normal expression of the hematopoietic growth factor receptor FLT3 (STK-1@Flk2) i
121                    Interleukin-3 (IL-3) is a hematopoietic growth factor receptor which stimulates th
122  important factors for regulating a critical hematopoietic growth factor receptor, the M-CSF receptor
123  genetic manipulation of NK cells to express hematopoietic growth factor receptors could be used as a
124 ively activating point mutations reported in hematopoietic growth factor receptors in patients with a
125 timulating factor receptor and several other hematopoietic growth factor receptors induce the tyrosin
126 nstream signaling events after activation of hematopoietic growth factor receptors.
127 after ex vivo culture in the presence of the hematopoietic growth factors recombinant murine stem cel
128                                 Prophylactic hematopoietic growth factor (recombinant human granulocy
129                                          The hematopoietic growth factors regulating these processes
130                                  Recombinant hematopoietic growth factors represent another therapeut
131                            Mpl ligand is the hematopoietic growth factor responsible for regulating t
132                         Stimulation of human hematopoietic growth factor responsive cell lines with s
133  cells isolated in vitro responded poorly to hematopoietic growth factors, resulting in an up to 11-f
134      In this report, involvement of Bcl-3 in hematopoietic growth factor-stimulated erythroid prolife
135 cyte-macrophage colony-stimulating factor, a hematopoietic growth factor, stimulates cells of the int
136                                      Several hematopoietic growth factors such as G-CSF, GM-CSF, and
137 es the possibility that excess expression of hematopoietic growth factors such as IL-3 and GM-CSF may
138 nous IFN-gamma affects the responsiveness to hematopoietic growth factors such as SCF in vitro, our r
139 ogeneic feeder cell layer, or IL-2 and other hematopoietic growth factors such as the c-kit ligand (K
140  compounds affected SCF synergism with other hematopoietic growth factors, such as interleukin-3 or g
141 gressive postremission therapy or the use of hematopoietic growth factor support does not appear to i
142  targeted antibiotic therapy or prophylactic hematopoietic growth factor support.
143                                   To exploit hematopoietic growth factor synergy, we have sought to c
144                Treatment with Flt3 ligand, a hematopoietic growth factor that dramatically expands th
145                        Flt3 ligand (FL) is a hematopoietic growth factor that induces proliferation a
146                  Stem cell factor (SCF) is a hematopoietic growth factor that interacts with the rece
147     Colony-stimulating factor-1 (CSF-1) is a hematopoietic growth factor that is released by osteobla
148 phage colony-stimulating factor (M-CSF) is a hematopoietic growth factor that is responsible for the
149 ocyte colony-stimulating factor (G-CSF) is a hematopoietic growth factor that is widely used to treat
150                             FLT3 ligand is a hematopoietic growth factor that plays a key role in gro
151                          Thrombopoietin is a hematopoietic growth factor that regulates the productio
152                    Thrombopoietin (TPO) is a hematopoietic growth factor that stimulates megakaryocyt
153                          Thrombopoietin is a hematopoietic growth factor that stimulates megakaryopoi
154  Mpl ligands are a family of closely related hematopoietic growth factors that bind to the thrombopoi
155 actors including VEGF, bFGF, IL-8, PDGF, and hematopoietic growth factors that promote endothelial ce
156 ctor (SLF) acts synergistically with various hematopoietic growth factors that use the Jak-Stat pathw
157 ority of tumors that do not directly secrete hematopoietic growth factors, the mechanisms involved in
158        When cultured on semisolid media with hematopoietic growth factors, these hematopoietic precur
159 rapy for depression and the selective use of hematopoietic growth factors to ameliorate hematologic a
160 stem cells and retrovirus transduction using hematopoietic growth factors to introduce a reporter gen
161                                  Recombinant hematopoietic growth factors were introduced into clinic
162                                              Hematopoietic growth factors were not allowed.
163                                 Prophylactic hematopoietic growth factors were not permitted.
164                                              Hematopoietic growth factors were not routinely used.
165                                 Prophylactic hematopoietic growth factors were not used.
166                                              Hematopoietic growth factors were used in 38% of episode
167 ogenitor cell mobilization is the ability of hematopoietic growth factors with distinct cellular targ
168 ulocyte colony-stimulating factor (G-CSF), a hematopoietic growth factor, with or without dexamethaso

 
Page Top